In some meta-analyses, CHEK2*1100delC heterozygotes have a two-fold risk of malignant melanoma (18).In addition, Złowocka et al. have found that CHEK2 mutations increase the risk of bladder cancer (19). Here, CHEK2 is linked to urinary bladder cancer.